Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.53 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.53 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.53 |
| ▸ | CA2 known ✓ | P00918 | 8/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34362 | 0.98 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| Ammonia Solution, Strong SCHEMBL28173213 | 0.96 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| Bicarbonate SCHEMBL4130667 | 0.94 | MEN1 (0.56) | TDP1MEN1GAAKMT2AMAOA | |
| Acetic Acid SCHEMBL8853938 | 0.92 | MEN1 (0.54) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL31574412 | 0.90 | MEN1 (0.53) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL5199631 | 0.89 | MAOA (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL6512546 | 0.89 | MAOA (0.55) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL5973450 | 0.88 | TDP1 (0.62) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1307836 | 0.86 | MAOA (0.57) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL6384884 | 0.86 | MAOA (0.57) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114748642-A | Tetravalent platinum drug-polymer conjugate nano micelle and preparation method and application thereof | 江西本草天工科技有限责任公司 | 2022-07-15 | — | — | CN | claimed |
| CN-122070279-A | Fibroblast activation protein inhibitor | 苏州博锐创合医药有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | disclosed |
| EP-4596535-A1 | DRUG FOR TREATING HUMAN TUMOR BY ERF3A TARGETED PROTEIN DEGRADATION MECHANISM | Suzhou Degen Bio-Medical Co, Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | SUZHOU DEGEN BIO-MEDICAL CO., LTD. (CN) | 2025-07-03 | — | — | US | disclosed |
| CN-119684336-A | Bisubstituted tribranched fluoroborodipyrrole compound containing active functional group, preparation method thereof and nucleophilic substitution product | 南京航空航天大学 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025026226-A1 | POLYETHYLENE GLYCOL SMALL MOLECULE DRUG, PREPARATION METHOD THEREFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2025-02-06 | — | — | WO | disclosed |
| CN-115926177-B | Polymer, polymer micelle, and preparation method and application thereof | 四川大学 | 2024-11-08 | — | — | CN | disclosed |
| EP-3978472-B1 | BIARYL MONABACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20070197465-A1 | Hyaluronic Acid-Methotrexate Conjugate | DENKI KAGAKU KABUSHIKI KAISHA (JP) | 2007-08-23 | — | — | US | disclosed |
| CN-1953965-A | Novel cis-imidazolines | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | CN | disclosed |
| US-20070054304-A1 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION OF PHOSPHORYLATED MOLECULES | INVITROGEN CORPORATION (US) | 2007-03-08 | — | — | US | disclosed |
| EP-1739097-A1 | HYALURONIC ACID/METHOTREXATE COMPOUND | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-01-03 | — | — | EP | disclosed |
| EP-1724287-A1 | HYALURONIC ACID/METHOTREXATE COMPOUND | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-20050288287-A1 | Chiral cis-imidazolines | FOTOUHI NADER | 2005-12-29 | — | — | US | disclosed |
| US-20050191643-A1 | Non-fluorescent carbocyanine quencher, molecular biology, immunology and fluorescence-based assays | MOLECULAR PROBES, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005047901-A2 | COMPOSITIONS AND METHODS FOR DETECTION AND ISOLATION PHOSPHORYLATED MOLECULES | MOLECULAR PROBES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050014197-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. | 2005-01-20 | — | — | US | disclosed |
| US-20040171034-A1 | Compositions and methods for detection and isolation of phosphorylated molecules | MOLECULAR PROBES, INC. | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191643-A1 | Non-fluorescent carbocyanine quencher, molecular biology, immunology and fluorescence-based assays | IDO1, IDO2, INMT | GAA 4262/4885MAOA 2903/4885MAOB 2052/4885 |
| US-20070197465-A1 | Hyaluronic Acid-Methotrexate Conjugate | CD44, MTX1, MTX2 | GAA 1806/4885MAOA 2327/4885MAOB 2928/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | GAA 3324/4885MAOA 4814/4885MAOB 4830/4885 |
| US-20250213701-A1 | MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM | XIAP, TP53, UBE3A | GAA 940/4885MAOA 3426/4885MAOB 2383/4885 |
| US-20260091081-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, MALT1, LY6K | GAA 3674/4885MAOA 4469/4885MAOB 4493/4885 |
| US-20050288287-A1 | Chiral cis-imidazolines | TP53, MDM2, TP53BP1 | GAA 3520/4885MAOA 4802/4885MAOB 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.